Cargando…
As Technologies for Nucleotide Therapeutics Mature, Products Emerge
The long path from initial research on oligonucleotide therapies to approval of antisense products is not unfamiliar. This lag resembles those encountered with monoclonal antibodies, gene therapies, and many biological targets and is consistent with studies of innovation showing that technology matu...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society of Gene & Cell Therapy
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686430/ https://www.ncbi.nlm.nih.gov/pubmed/29246316 http://dx.doi.org/10.1016/j.omtn.2017.10.017 |